
About Mirum Pharmaceuticals
Mirum Pharmaceuticals is a publicly listed company based in Menlo Park (United States) founded in 2018. Small molecule therapeutics are developed for rare diseases treatment. Mirum Pharmaceuticals has raised $120 million across 3 funding rounds from investors including Frazier Healthcare Partners, Oberland Capital and NEA. The company has 322 employees. Mirum Pharmaceuticals has completed 2 acquisitions, including Bluejay Therapeutics and Satiogen. Its chief executive, as recorded, is Christopher Peetz. Its website mirumpharma.com draws about 19 thousand monthly visits. Mirum Pharmaceuticals offers products and services including LIVMARLI, Cholbam, CTEXLI, and Diagnostic Testing Program. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Hepatic disorders. Its competitors include Alnylam, Ultragenyx and NGM Biopharmaceuticals; 3 of its 3 listed competitors have raised funding.
Company details
Mirum Pharmaceuticals was founded in 2018 and is headquartered in Menlo Park, United States. Small molecule therapeutics are developed by the company to address rare diseases, focusing on cholestatic conditions. The lead candidate, Maralixibat, is targeted at Alagille syndrome and progressive familial intrahepatic cholestasis by inhibiting bile acid transport. Volixibat is being advanced for adult cholestasis. Operations center on pharmaceutical research and development in the rare disease sector.
- Headquarters Menlo Park, United States
- Employees 322
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website mirumpharma.com
- Social LinkedIn X Facebook Instagram
- Legal Name Mirum Pharmaceuticals, Inc.
- Annual Revenue$521.31 M (USD)54.74as on Dec 31, 2025
- Net Profit-$23.36 M (USD)73.43as on Dec 31, 2025
- EBITDA$2.11 M (USD)as on Dec 31, 2025
- Total Equity Funding$120M (USD)
in 3 rounds
- Latest Funding Round$68.48M (USD), Post-IPO
Jan 2026
- InvestorsFrazier Healthcare Partners
& 7 more
- Employee Count322
- Investments & AcquisitionsBluejay Therapeutics
& 1 more
Products & Services of Mirum Pharmaceuticals
Mirum Pharmaceuticals offers a comprehensive portfolio of products and services, including LIVMARLI, Cholbam, CTEXLI, and Diagnostic Testing Program.
Treatment for cholestasis in rare diseases patients.
Therapy for inborn errors of bile acid metabolism.
Support for genetic neurology conditions in patients.
Program for testing rare diseases through healthcare partners.
Funding Insights of Mirum Pharmaceuticals
Mirum Pharmaceuticals has successfully raised a total of $120M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $68.48 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $120M
- Total Rounds 3
- Last Round Post-IPO β $68.48M
- First Round $120M
(Nov 2018)
- Investors Count 8
All 3 funding rounds of Mirum Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2026 | $68.48M | Post-IPO | β | β | β |
| Dec 2020 | $10M | Post-IPO | β | β | |
| Nov 2018 | $120M | Series A | β | New Enterprise Associates |
8 investors in total: 8 institutional.
Investors in Mirum Pharmaceuticals
Mirum Pharmaceuticals has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include Frazier Healthcare Partners, Oberland Capital and NEA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Structured financing solutions are provided for the global healthcare industry by Oberland Capital. | 2013 | oberlandcapital.com | New York, United States | |
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
VC firm focusing on life science sector | pappas-capital.com | Durham, United States | ||
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
| rivervest.com |
Investor details for Mirum Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Mirum Pharmaceuticals
164 people are tracked at Mirum Pharmaceuticals (100 in leadership, 9 in board & advisors, 55 in team); the tracked headcount is 322.
| Name | Role | Group |
|---|---|---|
Christopher Peetz | CEO | Leadership |
Chris Peetz | President & CEO | Leadership |
Lara Longpre | Chief Development Officer | Leadership |
Andrew McKibben | Vice President | Leadership |
Jolan Terner-Rosenthal | Executive Director, Publications | Leadership |
Peter Radovich | COO | Leadership |
Youngson Kim | Director Commercial Product QCQA | Leadership |
Nataliia Menon | Associate Director International Distributor Management | Leadership |
Kathy Chu | Director, Global Forecasting | Leadership |
Luis Polo-Carbayo | Associate Director, Post Marketing Studies Management | Leadership |
Jennifer Whaley | Regional Director Of Msls / West Region | Leadership |
Emmanuelle Nuris-Souquet | General Manager France And Benelux | Leadership |
Eva Ruth | Senior Director Of Gcp/gvp/glp QA | Leadership |
Jeffrey Murtha | Executive Director, Head Of US Metabolic Sales | Leadership |
Jody Legg | Sr. Director, Head US Payer Function | Leadership |
Philipp Anstaett-Pfeifer | Director Commercial Operations | Leadership |
Renee Shiota | Senior Director, Trade, Distribution And Patient Services | Leadership |
Anita Dreyer | Director Clinical Development | Leadership |
Jj Roth | Sr National Account Director, Managed Markets | Leadership |
Marc Clausse | Vp, International Commercial Operations | Leadership |
144 more people are available in the full profile.
Complete people profiles for Mirum Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Mirum Pharmaceuticals
Mirum Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol MIRM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date18 Jul 2019
- Listed onNASDAQ: MIRM
- Listed entityMirum Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS6047491013
- Share price$79.62 (-7.48% on the day) · 2026-10-13
- Market capitalisation$5.17B
- EPS (diluted, trailing year)$-14.55
- Volume (last session)762,633
Financials of Mirum Pharmaceuticals
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $521.3M | -$23.4M | $2.1M |
| 2024 | $336.9M | -$87.9M | -$64.0M |
| 2023 | $186.4M | -$163.4M | -$98.3M |
| 2022 | $77.1M | -$135.7M | -$127.5M |
| 2021 | $19.1M | -$84.0M | -$172.4M |
Detailed financial statements for Mirum Pharmaceuticals
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mirum Pharmaceuticals
Mirum Pharmaceuticals has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bluejay Therapeutics and Satiogen.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapeutics for infectious diseases treatment are developed. | bluejaytx.com | San Francisco, United States | 2019 | Dec 2025 | $620M | |
Specialty pharma company focused on developing treatment for
diabetes | satiogen.com | San Diego, United States | 2007 | May 2022 | β’β’β’β’ |
Complete acquisition details for Mirum Pharmaceuticals
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Mirum Pharmaceuticals
6 dated milestones of Mirum Pharmaceuticals across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Mirum Pharmaceuticals is founded.
- Funding First funding round of $120.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Satiogen.
- Acquisition Acquires Bluejay Therapeutics.
- Funding Latest funding round, Post-IPO, of $68.5M.
Competitors of Mirum Pharmaceuticals
Mirum Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Alnylam, Ultragenyx and NGM Biopharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. |
Detailed competitors of Mirum Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Mirum Pharmaceuticals
The website of Mirum Pharmaceuticals (mirumpharma.com) receives about 18.5K visits a month and ranks #1,354,049 among all websites worldwide, #1,754 in Biotechnology and Pharmaceuticals.
- Monthly visits18.5K
- Unique visitors8.4K
per month
- Global rank#1,354,049
among all websites
- Category rank#1,754
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit2.2
- Average visit1 min 06 sec
- DevicesDesktop 66% Β· Mobile 34%
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Mirum Pharmaceuticals (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mirum Pharmaceuticals
Complete news archive for Mirum Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mirum Pharmaceuticals
Mirum Pharmaceuticals was founded in 2018.
Mirum Pharmaceuticals is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Christopher Peetz is the CEO of Mirum Pharmaceuticals, as recorded in our data.
Mirum Pharmaceuticals is a funded company, having raised a total of $120M across 3 funding rounds to date. The company's 1st funding round was a Series A of $120M, raised on Nov 2018.
Mirum Pharmaceuticals has 322 employees.
Annual revenue of Mirum Pharmaceuticals is $521.31M as on Dec 31, 2025.
Mirum Pharmaceuticals was founded in 2018 and is headquartered in Menlo Park, United States. Small molecule therapeutics are developed by the company to address rare diseases, focusing on cholestatic conditions. The lead candidate, Maralixibat, is targeted at Alagille syndrome and progressive familial intrahepatic cholestasis by inhibiting bile acid transport. Volixibat is being advanced for adult cholestasis. Operations center on pharmaceutical research and development in the rare disease sector.
Mirum Pharmaceuticals's top competitors include Alnylam, NGM Biopharmaceuticals and Ultragenyx.
Mirum Pharmaceuticals offers LIVMARLI, Cholbam, CTEXLI, and Diagnostic Testing Program.
Yes, Mirum Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol MIRM.
Mirum Pharmaceuticals has made 2 acquisitions, including Bluejay Therapeutics, and Satiogen.
Mirum Pharmaceuticals has 8 investors. Key investors include Frazier Healthcare Partners, Oberland Capital, NEA, Deerfield, and Novo Holdings.
